Cargando…

Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

PURPOSE: A 3-biomarker homologous recombination deficiency (HRD) score is a key component of a currently FDA-approved companion diagnostic assay to identify HRD in patients with ovarian cancer using a threshold score of ≥ 42, though recent studies have explored the utility of a lower threshold (GIS ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lenz, Lauren, Neff, Chris, Solimeno, Cara, Cogan, Elizabeth S., Abramson, Vandana G., Boughey, Judy C., Falkson, Carla, Goetz, Matthew P., Ford, James M., Gradishar, William J., Jankowitz, Rachel C., Kaklamani, Virginia G., Marcom, P. Kelly, Richardson, Andrea L., Storniolo, Anna Maria, Tung, Nadine M., Vinayak, Shaveta, Hodgson, Darren R., Lai, Zhongwu, Dearden, Simon, Hennessy, Bryan T., Mayer, Erica L., Mills, Gordon B., Slavin, Thomas P., Gutin, Alexander, Connolly, Roisin M., Telli, Melinda L., Stearns, Vered, Lanchbury, Jerry S., Timms, Kirsten M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Original Laboratory Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504389/ https://www.ncbi.nlm.nih.gov/pubmed/37589839 http://dx.doi.org/10.1007/s10549-023-07046-3

Ejemplares similares

Automated lesion detection of breast cancer in [(18)F] FDG PET/CT using a novel AI-Based workflow
por: Leal, Jeffrey P., et al.
Publicado: (2022)

Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
por: Soliman, Hatem, et al.
Publicado: (2020)

Computational Method for Estimating DNA Copy Numbers in Normal Samples, Cancer Cell Lines, and Solid Tumors Using Array Comparative Genomic Hybridization
por: Abkevich, Victor, et al.
Publicado: (2010)

TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
por: Anders, Carey, et al.
Publicado: (2014)

Optimizing Vitamin D Concentrations for Breast Cancer Risk Reduction
por: Stearns, Vered, et al.
Publicado: (2013)

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer
por: Hertz, Daniel L., et al.
Publicado: (2016)

Innovating and expanding weight loss strategies for breast cancer survivors
por: Sheng, Jennifer Y., et al.
Publicado: (2021)

Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model
por: Gallagher, Shannon, et al.
Publicado: (2021)

Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
por: Timms, Kirsten M, et al.
Publicado: (2014)

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer
por: Doherty, Mary R., et al.
Publicado: (2017)

A randomized intervention involving family to improve communication in breast cancer care
por: Wolff, Jennifer L., et al.
Publicado: (2021)

Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes
por: Gallagher, Shannon, et al.
Publicado: (2020)

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
por: Kadakia, Kunal C., et al.
Publicado: (2016)

Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors
por: Wang, Hanwen, et al.
Publicado: (2020)

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
por: Patel, Jai N., et al.
Publicado: (2018)

Taxanes for the Treatment of Metastatic Breast Cancer
por: Gradishar, W.J.
Publicado: (2012)

Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
por: Constantinidou, Anastasia, et al.
Publicado: (2022)

Differences Are Important: Breast Cancer Therapy in Different Ethnic Groups
por: Costa, Ricardo L.B., et al.
Publicado: (2017)

The association between age at breast cancer diagnosis and prevalence of pathogenic variants
por: Daly, Mary B., et al.
Publicado: (2023)

CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005)

Management of advanced breast cancer with the epothilone B analog, ixabepilone
por: Gradishar, William
Publicado: (2009)

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects
por: Henry, N L, et al.
Publicado: (2013)

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer
por: How, Jeffrey A., et al.
Publicado: (2021)

Concurrent chemotherapy with partial breast irradiation in triple negative breast cancer patients may improve disease control compared with sequential therapy
por: Rhome, Ryan, et al.
Publicado: (2023)

Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk
por: Hughes, Elisha, et al.
Publicado: (2020)

Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition
por: Hughes, Elisha, et al.
Publicado: (2022)

Lasting Impacts of the COVID-19 Pandemic on Breast Cancer Diagnosis and Treatment in the United States
por: Sturz, Jenna L., et al.
Publicado: (2023)

Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm
por: Davis, Andrew A., et al.
Publicado: (2012)

A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases
por: Joe, Natalie S., et al.
Publicado: (2021)

Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term
por: Jankowitz, Rachel C, et al.
Publicado: (2012)

Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
por: Gollamudi, Jahnavi, et al.
Publicado: (2016)

Current Considerations in Surgical Treatment for Adolescents and Young Women with Breast Cancer
por: Murphy, Brittany L., et al.
Publicado: (2022)

Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer
por: Reddy, S M, et al.
Publicado: (2013)

Role of Fcγ receptors in HER2-targeted breast cancer therapy
por: Musolino, Antonino, et al.
Publicado: (2022)

Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes
por: Philips, Santosh, et al.
Publicado: (2012)

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
por: Parsons, Heather A., et al.
Publicado: (2023)

Epigenetics in breast cancer: what's new?
por: Huang, Yi, et al.
Publicado: (2011)

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
por: Hodgson, Darren R., et al.
Publicado: (2018)

Breast MRI contrast enhancement kinetics of normal parenchyma correlate with presence of breast cancer
por: Wu, Shandong, et al.
Publicado: (2016)

A case of synchronous breast and bilateral lung cancers: literature review and considerations for radiation treatment planning
por: Jin, Chunzi Jenny, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l72u31luj2sjqoneldd083flva